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Objective: To report a case of anterior uveitis after subconjunctival 
mitomycin C injection in a patient with a history of trabeculectomy.
Case Report: A 45 year old patient, with anterior uveitis in his 
right eye after postoperative injection of mitomycin C one month 
after trabeculectomy, was treated in Basir eye clinic, Tehran, Iran. 
The Patient had no history of previous ocular infection. Topical 
prednisolone and tropicamide drops were effective in improving 
vision and reducing pain in our case.
Conclusion: Anterior uveitis might happen after trabeculectomy 
surgery; however, in our case, it was more likely the result of 
mitomycin C administration one month after trabeculectomy. This 
should be considered as a differential diagnosis of postoperative 
bleb infections.
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Introduction
Mitomycin C (MMC) is an antibiotic, anticancer 
drug with widespread applications in 
ophthalmologic surgeries 1. The use of MMC in 
glaucoma surgeries prevents additional fibrosis 
or vascular ingrowth 1.  Although episodes 
of uveitis after trabeculectomy surgery with/
without mitomycin C application have been 
described previously 2, our case developed 
uveitis after outpatient administration of 
mitomycin C one month postoperatively. 
This case report was approved by the ethics 
committee of Basir Eye Health Research 
Center, Tehran, Iran, and written consent was 
obtained from the patient before reporting the 
case.
Case report
Here we report a 45-years-old male patient, 
with cystic encapsulated bleb in his right eye 
observed in his routine post-surgical checkup 
one month after trabeculectomy. The patient 
was Phakic without any previous history of 
systemic inflammatory diseases. The patient 
had normal findings in day 1, 3, 7 and 14 
postoperative follow-ups with no sign of 
inflammation and was under treatment with 
betamethasone eye drop twice a day. In the last 
postoperative visit one month after surgery 
the patient had visual acuity of 0.8 (0.0969 
LogMAR) and intraocular pressure (IOP) of 
21 in the right eye. In slit lamp examination, 
a cystic encapsulated bleb was observed. We 
decided to use needling to treat the cystic 
encapsulated bleb. Patient underwent topical 
anesthesia with tetracaine hydrochloride 0.5 
%. Needling was performed with a 27-gauge 
needle after instillation of 5 % povidone-iodine 
in fornices to break down the encapsulation and 
was continued with subsequent subconjunctival 
injection of MMC (0.1 cc 0.02 %). Three 
days after MMC injection, the patient came 
back with severe pain and visual acuity of 
0.1 lines (1 LogMAR) in his right eye. The 
patient indicated that the pain had started just 
six hours after MMC injection. In physical 
examination, diffuse conjunctival injection 
without prominent bleb involvement, posterior 
synechiae, anterior chamber cell and flare 
with clear vitreous were observed (Figure 1). 
Due to several observations we decided to 
treat our patient with a diagnosis of anterior 
uveitis due to MMC injection and ruled out the 
possibility of infectious blebitis. Our reasons 
for this diagnosis were the presence of diffuse 
conjunctival injection without prominent bleb 
involvement, lack of typical white on red 
view indicative of blebitis, and initiation of 
patients symptoms just six hours after MMC 
injection, which was strongly indicative of a 
not infectious inflammatory reaction since 
infectious inflammations usually take at least 
24 hours to show their symptoms. Standard 
treatment of anterior uveitis was initiated as 
prednisolone 1 % eye drop each 2 hours in 
first 2 days with tapering to two times a day 
for 30 days and tropicamide 1 % eye drop each 
8 hours. We observed immediate improvement 
of patient’s findings and followed the patient 
closely. Decreased pain and notable improved 
vision were documented after one month. 
Although posterior synechiae remained, visual 
acuity improved from 0.1 (1 logMAR) to 0.8 
(0.0969 LogMAR), anterior chamber clarity 
improved and IOP reached 18 at the end of one 
month follow up period (Figure 2).
Discussion
Anterior uveitis might happen after 
trabeculectomy surgery; however, in 
our case, it was more likely the result of 
mitomycin C administration one month after 
trabeculectomy. This should be considered as 
a differential diagnosis of postoperative bleb 
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 Figure 1: Right eye of patient after subconjunctival MMC injection
 Figure 2: Right eye of patient after standard treatment of uveitis
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infections. Subconjunctival MMC injection 
has a higher risk of toxicity compared to 
topical administration. 
Few researchers have investigated the 
application of MMC by subconjunctival 
injection both in experimental and human 
filtration surgeries. Gandolfi et al 3., injected 
subconjunctival MMC (0.5 ml, 0.2 %) in 
patients without any history of filtration surgery 
and IOP was decreased notably without any 
local complication. We applied a much lower 
dosage in our case (0.1 ml, 0.02 %) Although 
post-surgical anterior uveitis is usually related 
to trabeculectomy surgery itself; however, 
in our case, it was more likely the result 
of MMC administration one month after 
trabeculectomy. This should be considered as 
a differential diagnosis of postoperative bleb 
infections.
Conclusion
To the best of our knowledge, the present 
study is the first case report of anterior 
uveitis after low dose subconjunctival 
injection of MMC in a patient with 
previous trabeculectomy. It seems that 
anterior uveitis is a rare side effect after 
subconjunctival MMC injection and should 
be considered in differential diagnosis of 
postoperative blebitis in glaucoma patients.
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